127 related articles for article (PubMed ID: 8747385)
1. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials.
Ruffin MT; Ogaily MS; Johnston CM; Gregoire L; Lancaster WD; Brenner DE
J Cell Biochem Suppl; 1995; 23():113-24. PubMed ID: 8747385
[TBL] [Abstract][Full Text] [Related]
2. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
4. Cervical intraepithelial neoplasia.
Crum CP; McLachlin CM
J Cell Biochem Suppl; 1995; 23():71-9. PubMed ID: 8747380
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of cervical cancer.
Sasieni P
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):295-305. PubMed ID: 16386963
[TBL] [Abstract][Full Text] [Related]
7. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer.
Dhingra K
J Cell Biochem Suppl; 1995; 23():19-24. PubMed ID: 8747374
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers and their use in cervical cancer chemoprevention.
Vlastos AT; Schottenfeld D; Follen M
Crit Rev Oncol Hematol; 2003 Jun; 46(3):261-73. PubMed ID: 12791426
[TBL] [Abstract][Full Text] [Related]
9. Development of chemopreventive agents for lung and upper aerodigestive tract cancers.
Kelloff GJ; Boone CW; Steele VK; Perloff M; Crowell J; Doody LA
J Cell Biochem Suppl; 1993; 17F():2-17. PubMed ID: 8412195
[TBL] [Abstract][Full Text] [Related]
10. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
11. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials.
Follen M; Schottenfeld D
Cancer; 2001 May; 91(9):1758-76. PubMed ID: 11335902
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers.
Follen M; Meyskens FL; Alvarez RD; Walker JL; Bell MC; Storthz KA; Sastry J; Roy K; Richards-Kortum R; Cornelison TL
Cancer; 2003 Nov; 98(9 Suppl):2044-51. PubMed ID: 14603541
[TBL] [Abstract][Full Text] [Related]
13. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
16. Intermediate biomarkers of precancer and their application in chemoprevention.
Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
[TBL] [Abstract][Full Text] [Related]
17. High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the Cervista HPV HR test.
Gold MA; Thomas MA; Huh WK; Sarto GE; Day SP
J Low Genit Tract Dis; 2013 Jan; 17(1):51-7. PubMed ID: 22885641
[TBL] [Abstract][Full Text] [Related]
18. Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995.
J Cell Biochem Suppl; 1995; 23():1-250. PubMed ID: 8786651
[No Abstract] [Full Text] [Related]
19. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
20. [Correlations between the HPV type, DNA index and evolution of cervical intraepithelial neoplasia (CIN)].
Sassi I; Mangili F; Luchini S; Colombo G; Pezzotta MG; Candiani M; Frigerio A; Santambrogio G; Cantaboni A; Vignali M
Pathologica; 1993; 85(1095):79-84. PubMed ID: 8390639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
